Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer”

153 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 153 results

Large-scale testing (Phase 3)Study completedNCT02604342
What this trial is testing

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Who this might be right for
Non-small Cell Lung Cancer
Hoffmann-La Roche 119
Early research (Phase 1)Ended earlyNCT03087448
What this trial is testing

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
University of California, San Francisco 9
Testing effectiveness (Phase 2)Ended earlyNCT03131206
What this trial is testing

Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Who this might be right for
ALK-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Thyroid Cancer
Dana-Farber Cancer Institute 5
Not applicableLooking for participantsNCT05122806
What this trial is testing

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

Who this might be right for
Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie 100
Early research (Phase 1)Ended earlyNCT02511184
What this trial is testing

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Who this might be right for
ALK-positive Advanced NSCLC
Pfizer 9
Testing effectiveness (Phase 2)Study completedNCT01752400
What this trial is testing

AUY922 for Advanced ALK-positive NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Massachusetts General Hospital 6
Testing effectiveness (Phase 2)Looking for participantsNCT06092086
What this trial is testing

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC

Who this might be right for
ALK Positive Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 126
Early research (Phase 1)Active Not RecruitingNCT02321501
What this trial is testing

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+3 more
M.D. Anderson Cancer Center 37
Early research (Phase 1)Study completedNCT02299505
What this trial is testing

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 306
Not applicableStudy completedNCT04087473
What this trial is testing

Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

Who this might be right for
Non-small Cell Lung CancerALK-Positive Lung Cancer
National Cancer Centre, Singapore 50
Testing effectiveness (Phase 2)UnknownNCT04237805
What this trial is testing

A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Advanced CancerAdvanced Solid TumorLung Cancer, Nonsmall Cell
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 280
Testing effectiveness (Phase 2)Active Not RecruitingNCT05200481
What this trial is testing

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Who this might be right for
Non Small Cell Lung CancerALK Gene Mutation
Intergroupe Francophone de Cancerologie Thoracique 110
Testing effectiveness (Phase 2)UnknownNCT04056572
What this trial is testing

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
ALK-positive NSCLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 135
Testing effectiveness (Phase 2)Looking for participantsNCT05241028
What this trial is testing

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Hebei Medical University Fourth Hospital 80
Large-scale testing (Phase 3)Study completedNCT03194893
What this trial is testing

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Who this might be right for
Neoplasms
Hoffmann-La Roche 50
Testing effectiveness (Phase 2)Study completedNCT02094573
What this trial is testing

Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Ariad Pharmaceuticals 222
Not applicableLooking for participantsNCT06862869
What this trial is testing

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche 800
Testing effectiveness (Phase 2)UnknownNCT05869162
What this trial is testing

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Who this might be right for
Non-small-cell Lung Carcinoma
Shouyao Holdings (Beijing) Co. LTD 153
Not applicableActive Not RecruitingNCT05735327
What this trial is testing

Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Takeda 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT05491811
What this trial is testing

Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 47
Next Page